Primary |
Asthma |
33.3% |
Chronic Obstructive Pulmonary Disease |
22.2% |
Dyspnoea |
11.1% |
Prophylactic |
11.1% |
Respiratory Distress |
11.1% |
Wheezing |
11.1% |
|
Drug Ineffective |
22.2% |
Palpitations |
22.2% |
Hyperhidrosis |
11.1% |
Loss Of Consciousness |
11.1% |
Product Formulation Issue |
11.1% |
Product Quality Issue |
11.1% |
Weight Increased |
11.1% |
|
Secondary |
Asthma |
25.8% |
Chronic Obstructive Pulmonary Disease |
24.7% |
Sinusitis |
10.1% |
Arthritis |
4.5% |
Blood Pressure Increased |
4.5% |
Emphysema |
3.4% |
Hypertension |
3.4% |
Allergic Sinusitis |
2.2% |
Alpha-1 Anti-trypsin Deficiency |
2.2% |
Arthralgia |
2.2% |
Dyspnoea |
2.2% |
Muscle Spasms |
2.2% |
Neck Pain |
2.2% |
Pain |
2.2% |
Prophylaxis |
2.2% |
Abdominal Discomfort |
1.1% |
Anemia |
1.1% |
Anxiety Disorder Due To A General Medical Condition |
1.1% |
Attention Deficit/hyperactivity Disorder |
1.1% |
Back Pain |
1.1% |
|
Off Label Use |
28.6% |
Pneumonia |
21.4% |
Asthma |
7.1% |
Leukaemia |
7.1% |
Skin Discolouration |
7.1% |
Tremor |
7.1% |
Vomiting |
7.1% |
Weight Increased |
7.1% |
Wheezing |
7.1% |
|
Concomitant |
Product Used For Unknown Indication |
28.9% |
Chronic Obstructive Pulmonary Disease |
22.1% |
Asthma |
11.7% |
Hypertension |
5.2% |
Gastrooesophageal Reflux Disease |
3.7% |
Rheumatoid Arthritis |
3.2% |
Anxiety |
2.9% |
Emphysema |
2.9% |
Depression |
2.5% |
Pain |
2.4% |
Blood Cholesterol Increased |
2.3% |
Diabetes Mellitus |
1.6% |
Crohn's Disease |
1.6% |
Hypersensitivity |
1.4% |
Arthritis |
1.4% |
Atrial Fibrillation |
1.4% |
Dyspnoea |
1.3% |
Cardiac Disorder |
1.2% |
Hypothyroidism |
1.2% |
Vitamin Supplementation |
1.2% |
|
Product Quality Issue |
17.0% |
Dyspnoea |
10.7% |
Wheezing |
7.1% |
Incorrect Route Of Drug Administration |
6.7% |
Off Label Use |
6.7% |
Pneumonia |
6.7% |
Vomiting |
5.9% |
Drug Ineffective |
4.3% |
Injection Site Pain |
4.3% |
Nausea |
3.6% |
Sinusitis |
3.2% |
Urticaria |
3.2% |
Pain |
2.8% |
Pain In Extremity |
2.8% |
Throat Irritation |
2.8% |
Tremor |
2.8% |
Oedema Peripheral |
2.4% |
Rash |
2.4% |
Visual Impairment |
2.4% |
Weight Decreased |
2.4% |
|